GA
NTLA icon

GFS Advisors’s Intellia Therapeutics NTLA Stock Holding History

GFS Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.82M Buy
+130
New +$1.82K 0.61% 48

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

GFS Advisors's NTLA Position: Q2 2026 in Review

GFS Advisors opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 130 shares worth $5.82M. The stake represents 0.61% of the portfolio and ranks #48 among its holdings.

327 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • GFS Advisors held 130 shares of Intellia Therapeutics worth $5.82M as of Q2 2026.
  • Intellia Therapeutics was a new GFS Advisors position in Q2 2026.
  • Intellia Therapeutics made up 0.61% of GFS Advisors's portfolio in Q2 2026, its #48 holding.
  • 327 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on GFS Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.